NBIX: Neurocrine Biosciences Inc. Stocks News on October 18, 2024

State Street Corp's Strategic Acquisition in Neurocrine Biosciences Inc

NBIX

GuruFocus.com

10 hours ago

State Street Corp's Strategic Acquisition in Neurocrine Biosciences Inc

NBIX

Insider Monkey

a day ago

Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds?

Exploring Three High Growth Tech Stocks in the United States

NBIX

Simply Wall St.

7 days ago

Exploring Three High Growth Tech Stocks in the United States

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

NBIX

PR Newswire

8 days ago

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results

NBIX

Argus Research

9 days ago

NBIX: Lowering target price to $117.00

NBIX

MT Newswires

14 days ago

RBC Trims Price Target on Neurocrine Biosciences to $133 From $136, Keeps Sector Perform Rating

NBIX

Simply Wall St.

15 days ago

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

NBIX

PR Newswire

18 days ago

Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

NBIX

PR Newswire

a month ago

Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit

NBIX

MT Newswires

a month ago

Voyager Therapeutics Says Third Gene Therapy Development Candidate Selected Under Neurocrine Collaboration

NBIX

Insider Monkey

a month ago

Neurocrine Biosciences, Inc. (NBIX): Hedge Funds Are Bullish on This Aggressive Growth Stock

Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint

NBIX

Clinical Trials Arena

a month ago

Neurocrine’s Phase II schizophrenia trial fails to meet primary endpoint

NBIX

MT Newswires

a month ago

Neurocrine Plans to Halt Luvadaxistat Development After Study Fails to Meet Target

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

NBIX

PR Newswire

a month ago

Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

NBIX

PR Newswire

a month ago

Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Nxera wins $35m after Phase II schizophrenia trial success

NBIX

Pharmaceutical Technology

a month ago

Nxera wins $35m after Phase II schizophrenia trial success

Why Neurocrine Biosciences Stock Was Tumbling This Week

NBIX

Motley Fool

2 months ago

Why Neurocrine Biosciences Stock Was Tumbling This Week

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock

NBIX

Benzinga

2 months ago

Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

NBIX

Zacks

2 months ago

Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results

Neurocrine reports positive data from Phase II schizophrenia treatment trial

NBIX

Clinical Trials Arena

2 months ago

Neurocrine reports positive data from Phase II schizophrenia treatment trial

NBIX

MT Newswires

2 months ago

RBC Cuts Price Target on Neurocrine Biosciences to $136 From $143, Keeps Sector Perform Rating

NBIX

MT Newswires

2 months ago

Piper Sandler Upgrades Neurocrine Biosciences to Overweight From Neutral, Adjusts PT to $159 From $131

Neurocrine Plummets 19% — Does It Still Have A Shot At This 'Significant Market Opportunity?'

NBIX

Investor's Business Daily

2 months ago

Neurocrine Plummets 19% — Does It Still Have A Shot At This 'Significant Market Opportunity?'

Neurocrine Biosciences to Participate at Investor Conferences in September

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences to Participate at Investor Conferences in September

NBIX

MT Newswires

2 months ago

Oppenheimer Cuts Neurocrine Biosciences Price Target to $192 From $219, Maintains Outperform Rating

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

NBIX

Benzinga

2 months ago

As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors

Neurocrine Bio Dives As Schizophrenia Trial Results Lag Peers

NBIX

Investor's Business Daily

2 months ago

Neurocrine Bio Dives As Schizophrenia Trial Results Lag Peers

Neurocrine’s mixed schizophrenia data disappoint Wall Street

NBIX

BioPharma Dive

2 months ago

Neurocrine’s mixed schizophrenia data disappoint Wall Street

NBIX

MT Newswires

2 months ago

Neurocrine Biosciences' Schizophrenia Drug Shows 'Significant' Symptom Reduction in Phase 2 Trial

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1117568 in Adults with Schizophrenia

NBIX

Argus Research

2 months ago

NBIX: Raising target price to $160.00

High Growth Tech And 2 Other Promising Tech Stocks

NBIX

Simply Wall St.

2 months ago

High Growth Tech And 2 Other Promising Tech Stocks

NBIX

Argus Research

2 months ago

NBIX: Raising target price to $157.00

NBIX

GuruFocus.com

2 months ago

Insider Sale: Director William Rastetter Sells 14,250 Shares of Neurocrine Biosciences Inc (NBIX)

NBIX

MT Newswires

2 months ago

Neurocrine Biosciences Insider Sold Shares Worth $2,090,333, According to a Recent SEC Filing

NBIX

MT Newswires

2 months ago

Neurocrine Biosciences Insider Sold Shares Worth $1,740,450, According to a Recent SEC Filing

NBIX

MT Newswires

2 months ago

Neurocrine Biosciences Insider Sold Shares Worth $2,120,347, According to a Recent SEC Filing

NBIX

Simply Wall St.

2 months ago

Statutory Profit Doesn't Reflect How Good Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are

Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

NBIX

PR Newswire

2 months ago

Neurocrine Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference

NBIX

Zacks

2 months ago

Is Neurocrine (NBIX) a Solid Growth Stock? 3 Reasons to Think "Yes"

NBIX

MT Newswires

2 months ago

RBC Adjusts Neurocrine Biosciences' PT to $143 From $136, Keeps Sector Perform Rating

Vir retreats from infectious disease; Vertex shelves AATD drugs

NBIX

BioPharma Dive

3 months ago

Vir retreats from infectious disease; Vertex shelves AATD drugs

NBIX

GuruFocus.com

3 months ago

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight

NBIX

MT Newswires

3 months ago

Wedbush Raises Price Target on Neurocrine Biosciences to $163 From $152, Maintains Outperform Rating

NBIX

Zacks

3 months ago

Compared to Estimates, Neurocrine (NBIX) Q2 Earnings: A Look at Key Metrics

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Q2 Adjusted Earnings, Revenue Climb -- Shares Up Pre-Bell

NBIX

Zacks

3 months ago

Neurocrine Biosciences (NBIX) Lags Q2 Earnings Estimates

NBIX

Associated Press Finance

3 months ago

Neurocrine: Q2 Earnings Snapshot

Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance

NBIX

Zacks

3 months ago

Insights Into Neurocrine (NBIX) Q2: Wall Street Projections for Key Metrics

NBIX

Zacks

3 months ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

NBIX

Argus Research

3 months ago

NBIX: Lowering target price to $153.00

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Rolls Out Ingrezza Sprinkle Capsules to Treat Tardive Dyskinesia, Chorea With Huntington's Disease

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

NBIX

Argus Research

3 months ago

NBIX: Raising target price to $155.00

NBIX

Zacks

3 months ago

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results

NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results

Top Medical Stocks to Buy for Growth & Performance

NBIX

Zacks

3 months ago

Top Medical Stocks to Buy for Growth & Performance

NBIX

Argus Research

3 months ago

NBIX: Raising target price to $150.00

NBIX

MT Newswires

3 months ago

RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing

NBIX

Argus Research

4 months ago

NBIX: Raising target price to $144.00

FDA grants priority review for Neurocrine’s crinecerfont NDAs

NBIX

Pharmaceutical Technology

4 months ago

FDA grants priority review for Neurocrine’s crinecerfont NDAs

NBIX

MT Newswires

4 months ago

Neurocrine Biosciences Says US FDA Accepts NDAs With Priority Review for Adrenal Gland Disease Drug

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

How Medicare drug price negotiations could hit pharma stocks

NBIX

Yahoo Finance Video

4 months ago

How Medicare drug price negotiations could hit pharma stocks

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

NBIX

Investor's Business Daily

4 months ago

Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans

NBIX

Simply Wall St.

4 months ago

Those who invested in Neurocrine Biosciences (NASDAQ:NBIX) five years ago are up 55%

Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024

NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

NBIX

PR Newswire

4 months ago

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

NBIX

MT Newswires

5 months ago

Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing

Neurocrine Biosciences to Participate at Investor Conferences in June

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences to Participate at Investor Conferences in June

NBIX

MT Newswires

5 months ago

Neurocrine Biosciences Says CEO Kevin Gorman Retiring

Neurocrine Biosciences Announces CEO Succession Plan

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Announces CEO Succession Plan

NBIX

MT Newswires

5 months ago

UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024

NBIX

MT Newswires

5 months ago

Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing

Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules

NBIX

MT Newswires

5 months ago

Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Presented Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers

NBIX

Investor's Business Daily

5 months ago

How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring

Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam

NBIX

Investor's Business Daily

5 months ago

Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

NBIX

PR Newswire

5 months ago

Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024

NBIX

MT Newswires

6 months ago

UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating

Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations

NBIX

Simply Wall St.

6 months ago

Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations

NBIX

GuruFocus.com

6 months ago

Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...

NBIX

GuruFocus.com

6 months ago

Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight

NBIX

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Neurocrine Biosciences Inc Earnings Call

NBIX

GuruFocus.com

6 months ago

Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements

Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech

NBIX

Investor's Business Daily

6 months ago

Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech

NBIX

Zacks

6 months ago

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win

NBIX

Investor's Business Daily

6 months ago

No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win

NBIX

MT Newswires

6 months ago

Latest Neurocrine Biosciences Inc. (NBIX) News on October 18, 2024

Share on Social Networks: